Syntara
CompanyAustralia
Syntara develops 3 assets, the furthest in phase 2 (Amsulostat in myelofibrosis). Mostly small molecule acting on inflammation, LOX and LOXL1; based in Australia.
- 3
- Assets
- Furthest
- Phase 2
- 3
- Trials
- 0
- Signals
Pipeline
3Inhibits lysyl oxidase family enzymes to prevent collagen cross-linking and fibrosis.
Phase 2, Small molecule, LOX, LOXL1, myelofibrosis
Inhibitor of SSAO/VAP-1 (and AOC3) reducing neuroinflammation and microglial activation
Phase 2, Small molecule, Inflammation, AOC3, REM sleep behavior disorder
Nitric oxide-donating derivative of budesonide with anti-inflammatory activity
Phase 2, Small molecule, NR3C1, Inflammation, copd bronchitis
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms3
- Trials3
- Similar companies6
Updated 7 Oct 2026 · 7 sources